Evolution of Pfdhps and Pfdhfr mutations before and after adopting seasonal malaria chemoprevention in Nanoro, Burkina Faso.
Burkina Faso
/ epidemiology
Humans
Tetrahydrofolate Dehydrogenase
/ genetics
Dihydropteroate Synthase
/ genetics
Mutation
Pyrimethamine
/ therapeutic use
Plasmodium falciparum
/ genetics
Antimalarials
/ therapeutic use
Sulfadoxine
/ therapeutic use
Drug Resistance
/ genetics
Infant
Malaria, Falciparum
/ prevention & control
Child, Preschool
Seasons
Amodiaquine
/ therapeutic use
Protozoan Proteins
/ genetics
Drug Combinations
Chemoprevention
/ methods
Male
Female
Malaria
/ prevention & control
Pfdhfr
Pfdhps
Plasmodium falciparum
Burkina Faso
SMC
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
16 10 2024
16 10 2024
Historique:
received:
04
06
2024
accepted:
04
10
2024
medline:
17
10
2024
pubmed:
17
10
2024
entrez:
16
10
2024
Statut:
epublish
Résumé
Seasonal Malaria Chemoprevention consisting of monthly administration of amodiaquine/sulfadoxine-pyrimethamine to children aged 3-59 months during the transmission season could promote SP-resistance. Mutations in dihydrofolate reductase (Pfdhfr) and dihydropteroate synthase (Pfdhps) genes were assessed before and after SMC adoption in Burkina Faso. A total of 769 dried blood spots were selected from studies conducted in Nanoro, Burkina Faso, between 2010 and 2020. Of those, 299 were pre-SMC (2010-2012) and 470 were post-SMC-samples. Pfdhps and Pfdhfr genes were PCR-amplified and sequenced. A systematic review/meta-analysis of published studies conducted in Burkina Faso (2009-2023) was additionally performed. In Nanoro, the prevalence of Pfdhfr triple mutations (CIRNI) rose from 43.6% pre-SMC to 89.4% post-SMC (p < 0.0001). There was no mutation in Pfdhfr 164 and Pfdhps 540; Pfdhps A437G mutation increased from 63.9% (2010-2012) to 84.7% (2020) (p < 0.0001). The VAGKGS haplotype was 2.8% (2020). Pfdhfr/Pfdhps quintuple mutant IRN-436A437G rose from 18.6% (2010-2012) to 58.3% (2020) (p < 0.0001). Meta-analysis results from Burkina Faso showed an increase in mutations at Pfdhfr N51I, C59R, S108N, and Pfdhps A437G after SMC adoption. Post-SMC, the pyrimethamine-resistance marker prevalence increased, while the sulfadoxine-resistance marker prevalence remained stable. Detection of emerging PfdhpsVAGKGS haplotypes in 2020 underscores the importance of continuous SP-resistance monitoring.
Identifiants
pubmed: 39414909
doi: 10.1038/s41598-024-75369-2
pii: 10.1038/s41598-024-75369-2
doi:
Substances chimiques
Tetrahydrofolate Dehydrogenase
EC 1.5.1.3
Dihydropteroate Synthase
EC 2.5.1.15
Pyrimethamine
Z3614QOX8W
Antimalarials
0
Sulfadoxine
88463U4SM5
fanasil, pyrimethamine drug combination
37338-39-9
Amodiaquine
220236ED28
Protozoan Proteins
0
Drug Combinations
0
DHFR protein, Plasmodium falciparum
EC 1.5.1.3
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
24224Informations de copyright
© 2024. The Author(s).
Références
World malaria report. (2023). n.d https://www.who.int/publications-detail-redirect/9789240086173 (accessed December 20, 2023).
ANNUAIRE STATISTIQUE 2021. Ministère Santé L’Hygiène Publique (2022). https://www.sante.gov.bf/detail-documents?tx_news_pi1%5Baction%5D=detail&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Bnews%5D=768&cHash=3 f0c7c2c393cf68c6a1086b0b22e2d28 (accessed December 20, 2023).
Organization, W. H. WHO policy recommendation: Seasonal malaria chemoprevention (SMC) for plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa 2012.
Updated WHO recommendations for malaria chemoprevention among children. and pregnant women n.d. accessed December 20, (2023). https://www.who.int/news/item/03-06-2022-Updated-WHO-recommendations-for-malaria-chemoprevention-among-children-and-pregnant-women
WHO Guidelines for malaria n.d. accessed December 19, (2023). https://www.who.int/publications-detail-redirect/guidelines-for-malaria
Cissé, B. et al. Seasonal intermittent preventive treatment with artesunate and sulfadoxine-pyrimethamine for prevention of malaria in Senegalese children: A randomised, placebo-controlled, double-blind trial. Lancet. 367, 659–667. https://doi.org/10.1016/S0140-6736(06)68264-0 (2006).
doi: 10.1016/S0140-6736(06)68264-0
pubmed: 16503464
Konaté, A. T. et al. Intermittent preventive treatment of Malaria provides Substantial Protection against Malaria in Children already protected by an insecticide-treated Bednet in Burkina Faso: A Randomised, Double-Blind, placebo-controlled trial. PLoS Med.. https://doi.org/10.1371/journal.pmed.1000408 (2011).
Druetz, T. et al. Impact Evaluation of Seasonal Malaria Chemoprevention under Routine Program implementation: A quasi-experimental study in Burkina Faso. Am. J. Trop. Med. Hyg. 98, 524–533. https://doi.org/10.4269/ajtmh.17-0599 (2018).
doi: 10.4269/ajtmh.17-0599
pubmed: 29260654
Meremikwu, M. M., Donegan, S., Sinclair, D., Esu, E. & Oringanje, C. Intermittent preventive treatment for malaria in children living in areas with seasonal transmission. Cochrane Database Syst. Rev. . (2012). https://doi.org/10.1002/14651858.CD003756.pub4
Kirakoya-Samadoulougou, F., De Brouwere, V., Fokam, A. F., Ouédraogo, M. & Yé, Y. Assessing the effect of seasonal malaria chemoprevention on malaria burden among children under 5 years in Burkina Faso. Malar. J. 21, 143. https://doi.org/10.1186/s12936-022-04172-z (2022).
doi: 10.1186/s12936-022-04172-z
pubmed: 35524310
pmcid: 9074217
Picot, S. et al. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar. J. 8, 89. https://doi.org/10.1186/1475-2875-8-89 (2009).
doi: 10.1186/1475-2875-8-89
pubmed: 19413906
pmcid: 2681474
Okell, L. C., Griffin, J. T. & Roper, C. Mapping sulphadoxine-pyrimethamine-resistant Plasmodium falciparum malaria in infected humans and in parasite populations in Africa. Sci. Rep. 7, 7389. https://doi.org/10.1038/s41598-017-06708-9 (2017).
doi: 10.1038/s41598-017-06708-9
pubmed: 28785011
pmcid: 5547055
Lynch, C. et al. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. J. Infect. Dis. 197, 1598–1604. https://doi.org/10.1086/587845 (2008).
doi: 10.1086/587845
pubmed: 18471065
Kavishe, R. A. et al. Molecular monitoring of Plasmodium Falciparum super-resistance to sulfadoxine-pyrimethamine in Tanzania. Malar. J. 15, 335. https://doi.org/10.1186/s12936-016-1387-2 (2016).
doi: 10.1186/s12936-016-1387-2
pubmed: 27339129
pmcid: 4918075
Tumwebaze, P. et al. Changing antimalarial drug resistance patterns identified by Surveillance at three sites in Uganda. J. Infect. Dis. 215, 631–635. https://doi.org/10.1093/infdis/jiw614 (2017).
doi: 10.1093/infdis/jiw614
pubmed: 28039354
Kateera, F. et al. Molecular surveillance of Plasmodium Falciparum drug resistance markers reveals partial recovery of chloroquine susceptibility but sustained sulfadoxine-pyrimethamine resistance at two sites of different malaria transmission intensities in Rwanda. Acta Trop. 164, 329–336. https://doi.org/10.1016/j.actatropica.2016.09.008 (2016).
doi: 10.1016/j.actatropica.2016.09.008
pubmed: 27647575
pmcid: 10600949
Peterson, D. S., Walliker, D. & Wellems, T. E. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. U S A. 85, 9114–9118. https://doi.org/10.1073/pnas.85.23.9114 (1988).
doi: 10.1073/pnas.85.23.9114
pubmed: 2904149
pmcid: 282674
Triglia, T., Menting, J. G. T., Wilson, C. & Cowman, A. F. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium Falciparum. Proc. Natl. Acad. Sci. U S A. 94, 13944–13949 (1997).
doi: 10.1073/pnas.94.25.13944
pubmed: 9391132
pmcid: 28412
Amimo, F. et al. Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in Africa: A systematic analysis of national trends. BMJ Glob. Health. 5, e003217. https://doi.org/10.1136/bmjgh-2020-003217 (2020).
doi: 10.1136/bmjgh-2020-003217
pubmed: 33214174
pmcid: 7678238
Meeting report of the Evidence Review Group on intermittent preventive. treatment (IPT) of malaria in pregnancy n.d. accessed May 16 (2024). https://www.who.int/publications/m/item/meeting-report-of-the-evidence-review-group-on-intermittent-preventive-treatment-of-malaria-in-pregnancy
Organization, W. H. WHO policy recommendation on intermittent preventive treatment during infancy with sulphadoxine-pyrimethamine (SP-IPTi) for plasmodium falciparum malaria control in Africa 2010.
Naidoo, I. & Roper, C. Mapping partially resistant, fully resistant, and super resistant malaria. Trends Parasitol. 29, 505–515. https://doi.org/10.1016/j.pt.2013.08.002 (2013).
doi: 10.1016/j.pt.2013.08.002
pubmed: 24028889
Omar, S. A., Adagu, I. S., Gump, D. W., Ndaru, N. P. & Warhurst, D. C. Plasmodium Falciparum in Kenya: High prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic area. Ann. Trop. Med. Parasitol. 95, 661–669. https://doi.org/10.1080/00034980120103234 (2001).
doi: 10.1080/00034980120103234
pubmed: 11784419
Staedke, S. G. et al. Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop. Med. Int. Health TM IH. 9, 624–629. https://doi.org/10.1111/j.1365-3156.2004.01239.x (2004).
doi: 10.1111/j.1365-3156.2004.01239.x
pubmed: 15117308
Kublin, J. G. et al. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium Falciparum malaria. J. Infect. Dis. 185, 380–388. https://doi.org/10.1086/338566 (2002).
doi: 10.1086/338566
pubmed: 11807721
Kweku, M. et al. Seasonal intermittent preventive treatment for the prevention of anaemia and malaria in Ghanaian children: A randomized, placebo controlled trial. PloS One. 3, e4000. https://doi.org/10.1371/journal.pone.0004000 (2008).
doi: 10.1371/journal.pone.0004000
pubmed: 19098989
pmcid: 2602973
Lo, A. C. et al. Prevalence of molecular markers of drug resistance in an area of seasonal malaria chemoprevention in children in Senegal. Malar. J. 12, 137. https://doi.org/10.1186/1475-2875-12-137 (2013).
doi: 10.1186/1475-2875-12-137
pubmed: 23617576
pmcid: 3652725
Oguike, M. C. et al. Molecular determinants of sulfadoxine-pyrimethamine resistance in Plasmodium Falciparum in Nigeria and the regional emergence of dhps 431V. Int. J. Parasitol. Drugs Drug Resist. 6, 220–229. https://doi.org/10.1016/j.ijpddr.2016.08.004 (2016).
doi: 10.1016/j.ijpddr.2016.08.004
pubmed: 27821281
pmcid: 5094156
Maiga, H. et al. Seasonal Malaria Chemoprevention with Sulphadoxine-Pyrimethamine and Amodiaquine selects pfdhfr-dhps quintuple mutant genotype in Mali. PloS One. 11, e0162718. https://doi.org/10.1371/journal.pone.0162718 (2016).
doi: 10.1371/journal.pone.0162718
pubmed: 27662368
pmcid: 5035027
Somé, A. F. et al. Selection of Drug Resistance-Mediating Plasmodium Falciparum genetic polymorphisms by Seasonal Malaria Chemoprevention in Burkina Faso. Antimicrob. Agents Chemother. 58, 3660–3665. https://doi.org/10.1128/AAC.02406-14 (2014).
doi: 10.1128/AAC.02406-14
pubmed: 24733476
pmcid: 4068591
Beshir, K. B. et al. Prevalence of Plasmodium Falciparum haplotypes associated with resistance to sulfadoxine–pyrimethamine and amodiaquine before and after upscaling of seasonal malaria chemoprevention in seven African countries: A genomic surveillance study. Lancet Infect. Dis.. https://doi.org/10.1016/S1473-3099(22)00593-X (2022).
de Cola, M. A. et al. Impact of seasonal malaria chemoprevention on prevalence of malaria infection in malaria indicator surveys in Burkina Faso and Nigeria. BMJ Glob Health. 7, e008021. https://doi.org/10.1136/bmjgh-2021-008021 (2022).
doi: 10.1136/bmjgh-2021-008021
pubmed: 35589153
pmcid: 9121431
Roh, M. E. et al. Seasonal Malaria Chemoprevention drug levels and drug resistance markers in children with or without Malaria in Burkina Faso: A case-control study. J. Infect. Dis. 228, 926–935. https://doi.org/10.1093/infdis/jiad172 (2023).
doi: 10.1093/infdis/jiad172
pubmed: 37221018
pmcid: 10547452
New guidelines on antenatal care. for a positive pregnancy experience n.d. accessed April 19, (2024). https://www.who.int/news/item/07-11-2016-new-guidelines-on-antenatal-care-for-a-positive-pregnancy-experience
Petersen, I., Eastman, R. & Lanzer, M. Drug-resistant malaria: Molecular mechanisms and implications for public health. FEBS Lett. 585, 1551–1562. https://doi.org/10.1016/j.febslet.2011.04.042 (2011).
doi: 10.1016/j.febslet.2011.04.042
pubmed: 21530510
Yamauchi, M., Hirai, M., Tachibana, S-I., Mori, T. & Mita, T. Fitness of sulfadoxine-resistant Plasmodium berghei harboring a single mutation in dihydropteroate synthase (DHPS). Acta Trop. 222, 106049. https://doi.org/10.1016/j.actatropica.2021.106049 (2021).
doi: 10.1016/j.actatropica.2021.106049
pubmed: 34273314
Rosenthal, P. J. The interplay between drug resistance and fitness in malaria parasites. Mol. Microbiol. 89, 1025–1038. https://doi.org/10.1111/mmi.12349 (2013).
doi: 10.1111/mmi.12349
pubmed: 23899091
pmcid: 3792794
Heinberg, A. et al. Direct evidence for the adaptive role of copy number variation on antifolate susceptibility in Plasmodium Falciparum. Mol. Microbiol. 88, 702–712. https://doi.org/10.1111/mmi.12162 (2013).
doi: 10.1111/mmi.12162
pubmed: 23347134
pmcid: 3654098
van Eijk, A. M. et al. Effect of Plasmodium Falciparum sulfadoxine-pyrimethamine resistance on the effectiveness of intermittent preventive therapy for malaria in pregnancy in Africa: A systematic review and meta-analysis. Lancet Infect. Dis. 19, 546–556. https://doi.org/10.1016/S1473-3099(18)30732-1 (2019).
doi: 10.1016/S1473-3099(18)30732-1
pubmed: 30922818
Desai, M. et al. Impact of sulfadoxine-pyrimethamine resistance on effectiveness of intermittent preventive therapy for Malaria in pregnancy at Clearing infections and preventing low Birth Weight. Clin. Infect. Dis. 62, 323–333. https://doi.org/10.1093/cid/civ881 (2016).
doi: 10.1093/cid/civ881
pubmed: 26486699
Gosling, R. D. et al. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: A randomised, double-blind, placebo-controlled trial. Lancet Lond. Engl. 374, 1521–1532. https://doi.org/10.1016/S0140-6736(09)60997-1 (2009).
doi: 10.1016/S0140-6736(09)60997-1
Consortium, C. et al. Community-based Malaria Screening and treatment for pregnant women receiving standard intermittent preventive treatment with Sulfadoxine-Pyrimethamine: A Multicenter (the Gambia, Burkina Faso, and Benin) cluster-randomized controlled trial. Clin. Infect. Dis. 68, 586–596. https://doi.org/10.1093/cid/ciy522 (2019).
doi: 10.1093/cid/ciy522
Kamya, M. R., Kakuru, A. & Dorsey, G. Dihydroartemisinin–piperaquine for prevention of malaria in pregnant women living with HIV. Lancet. 403, 327–330. https://doi.org/10.1016/S0140-6736(24)00048-5 (2024).
doi: 10.1016/S0140-6736(24)00048-5
pubmed: 38224711
Kakuru, A. et al. Impact of intermittent preventive treatment of malaria in pregnancy with dihydroartemisinin-piperaquine versus sulfadoxine-pyrimethamine on the incidence of malaria in infancy: A randomized controlled trial. BMC Med. 18, 207. https://doi.org/10.1186/s12916-020-01675-x (2020).
doi: 10.1186/s12916-020-01675-x
pubmed: 32772921
pmcid: 7416391
Savic, R. M. et al. Intermittent preventive treatment for Malaria in pregnancy: Optimization of target concentrations of dihydroartemisinin-piperaquine. Clin. Infect. Dis. 67, 1079–1088. https://doi.org/10.1093/cid/ciy218 (2018).
doi: 10.1093/cid/ciy218
pubmed: 29547881
pmcid: 6137112
Sutherland, C. J. et al. Novel pfdhps haplotypes among Imported cases of Plasmodium Falciparum Malaria in the United Kingdom. Antimicrob. Agents Chemother. 53, 3405–3410. https://doi.org/10.1128/AAC.00024-09 (2009).
doi: 10.1128/AAC.00024-09
pubmed: 19433569
pmcid: 2715629
Guémas, E. et al. Evolution and spread of Plasmodium falciparum mutations associated with resistance to sulfadoxine–pyrimethamine in central Africa: A cross-sectional study. Lancet Microbe. 4, e983–e993. https://doi.org/10.1016/S2666-5247(23)00211-2 (2023).
doi: 10.1016/S2666-5247(23)00211-2
pubmed: 37865113
Cohen, O. et al. Effect of sulfadoxine-pyrimethamine chemoprophylaxis in pregnant women on selection of the new P. Falciparum dhps quintuple mutant carrying the I431V mutation. J. Antimicrob. Chemother. 78, 665–668. https://doi.org/10.1093/jac/dkac432 (2023).
doi: 10.1093/jac/dkac432
pubmed: 36611259
Conseil national de la statistique n. d. accessed March 3, (2024). http://cns.bf/spip.php?id_rubrique=17&page=publdetails
Chimio-prévention du paludisme saisonnier. Ministère Santé L’Hygiène Publique (2020). https://www.sante.gov.bf/detail?tx_news_pi1%5Baction%5D=detail&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Bnews%5D=296&cHash=b409f2a6b9050eb61b72566521acd8a9 (accessed March 3, 2024).
Sondo, P. et al. Effectiveness and safety of artemether-lumefantrine versus artesunate-amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: A randomized open label trial. Malar. J. 14, 325. https://doi.org/10.1186/s12936-015-0843-8 (2015).
doi: 10.1186/s12936-015-0843-8
pubmed: 26289949
pmcid: 4545998
Rouamba, T. et al. High adherence level to artemisinin-based combination therapies in rural settlement 11 years after their introduction in the health system, Nanoro, Burkina Faso. Patient Prefer Adherence. 13, 371–380. https://doi.org/10.2147/PPA.S190927 (2019).
doi: 10.2147/PPA.S190927
pubmed: 30880921
pmcid: 6402368
Sondo, P. et al. Assessment of a combined strategy of seasonal malaria chemoprevention and supplementation with vitamin A, zinc and Plumpy’Doz
doi: 10.1186/s13063-021-05320-7
pubmed: 34030705
pmcid: 8142067
Duraisingh, M. T., Curtis, J. & Warhurst, D. C. Plasmodium Falciparum: Detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp. Parasitol. 89, 1–8. https://doi.org/10.1006/expr.1998.4274 (1998).
doi: 10.1006/expr.1998.4274
pubmed: 9603482
Kanai, M. et al. Comparative analysis of Plasmodium Falciparum genotyping via SNP Detection, microsatellite profiling, and whole-genome sequencing. Antimicrob. Agents Chemother. 66, e0116321. https://doi.org/10.1128/AAC.01163-21 (2022).
doi: 10.1128/AAC.01163-21
pubmed: 34694871
Crameri, A. et al. Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J. Clin. Microbiol. 45, 3685–3691. https://doi.org/10.1128/JCM.01178-07 (2007).
doi: 10.1128/JCM.01178-07
pubmed: 17804664
pmcid: 2168483